Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer Clinical Trial

— ICARUS-BREAST  

Official title:

Phase 2, Open Label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in Patients With Advanced Breast Cancer, With Biomarker Analyses to Characterize Response to Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04965766
• Other study ID #: 2020-005722-28
• Secondary ID: 2020/3188
• Status: Recruiting
• Phase: Phase 2
• Start date: May 11, 2021
• Est. completion date: June 11, 2026

Study information

• Verified date: May 2023
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: Barbara Pistilli, Dr
• Phone: +33 (0)1 42 11 42 11
• Email: barbara.pistilli[@]gustaveroussy.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate the efficacy and safety of U3-1402 in participants with advanced breast cancer (ABC). Participants have to be hormone-receptor positive (HR+) and have to be resistant to endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. Participants may have received multiple lines of endocrine therapy with or without targeted therapies and must have received only one line of chemotherapy for ABC. Moreover, the immune effects, the predictors of resistance and response to treatment, the effect of the chemotherapy on deoxyribonucleic acid (DNA) replication will be assessed and will help identify the subgroups that will mostly benefit from the treatment. The pharmacokinetics of the product and the anti-drug antibody (ADA) will be also evaluated. A total of 100 participants are planned to be treated in the study. Participants will receive, every three weeks, a dose of U3-1402 equivalent to 5.6 mg/kg of body weight until progression or until unacceptable toxicity. Tumor evaluation will be performed every six weeks by the mean of a computed tomography for the thorax, abdomen and pelvis (TAP CT-scan) or a magnetic resonance imaging (MRI). Brain and/or bone CT scans will be also performed throughout the study for participants with brain and/or bone metastasis. The safety of the product will be assessed at each cycle, through complete clinical exams, biological tests, electrocardiograms (ECGs), cardiac echographies (ECHOs) and through the collection of ongoing toxicities or adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: June 11, 2026
• Est. primary completion date: January 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults with histologically-confirmed HER2 negative, unresectable locally advanced or metastatic breast cancer that is hormone receptor positive (HR+) at the time of the first breast cancer diagnosis
• Participants with a documented radiologic unresectable or metastatic progression
• Participants may have received anthracyclines and taxanes as (neo) adjuvant treatment and must have received one line of chemotherapy for Advanced breast cancer (ABC), but not more than one line. Participants must have a clinically or radiologically documented evidence of tumor progression on or after cyclin dependent kinase 4/6 (CDK 4/ 6) inhibitor combined with endocrine therapy. Previous treatments with PI3K inhibitors, mTOR inhibitors, AKT-inhibitors and poly ADP ribose polymerase (PARP)-inhibitors are allowed
• Participants must have a tumor site easily accessible to biopsy (with exception of bone metastasis)
• Participants must have at least one radiologically measurable lesion (different from the biopsy site)
• Participants must have an ECOG PS equals to 0 or 1
• Participants must have a life expectancy of 12 weeks or more
• Participants must have adequate bone marrow reserve and organ function, based on local laboratory data within 14 days prior to Cycle 1, Day 1
• Females of reproductive/childbearing potential must have a negative pregnancy test at screening and must agree to use a highly effective form of contraception or avoid intercourse during the study and for at least 7 months after the last dose of study drug.

Contraceptive methods considered highly effective:

1. Intrauterine device (IUD)

2. Bilateral tubal occlusion

3. Vasectomized partner

4. Complete sexual abstinence during and upon completion of the study and for at least 7 months for females after the last dose of study drug Female participants must not donate, or retrieve for their own use, ova from the time of screening and for at least 7 months after the final study drug administration -If male, the participant must be surgically sterile, must withhold heterosexual intercourse, or must be willing to use a highly effective birth control upon enrollment, and for at least 4 months following the last dose of study drug Male participants must not freeze or donate sperm starting at screening and throughout the study period, and for at least 4 months after the final study drug administration

• Participant must understand, sign, and date the written ICF prior to any protocol-specific procedures performed. Participant should be able and willing to comply with study visits and procedure as per protocol
• Participant must be affiliated to a social security system or beneficiary of the same

Exclusion Criteria:

• Breast cancer amenable for resection or radiation therapy with curative intent
• Any history of interstitial lung disease (ILD), actual ILD, or a suspicion of an ILD
• Clinically severe pulmonary compromise (based on investigator's assessment) resulting

from intercurrent pulmonary illnesses including, but not limited to:

1. Any underlying pulmonary disorder

2. Any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement

3. OR prior pneumonectomy

• The use of chronic systemic corticosteroids at a dose superior to 10 mg of prednisone or equivalent or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled steroids, or local steroid injections may be included in the study
• Evidence of any leptomeningeal disease
• Evidence of corneal disease
• Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection, psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol
• Evidence of clinically active spinal cord compression or brain metastases defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
• Inadequate washout period prior to Cycle 1 Day 1, defined as:

1. Whole brain radiation therapy within 14 days before treatment or stereotactic brain radiation therapy, within 7 days before treatment

2. Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study, within 14 days before treatment or 5 half-lives, whichever is longer

3. Immune checkpoint inhibitor therapy, within 21 days before treatment

4. Endocrine therapy within 21 days of treatment

5. Major surgery (excluding placement of vascular access) within 28 days of treatment

6. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days or palliative radiation therapy within 14 days of treatment

7. Chloroquine or hydroxychloroquine within 14 days before treatment

8. Live virus vaccination, within 28 days before treatment

• Prior treatment with an anti-HER3 antibody and/or ADC containing an exatecan derivative that is a topoisomerase I inhibitor
• Participants with a grade equals or greater than 2 unresolved toxicities from previous anticancer therapy (other than alopecia)
• A history of severe hypersensitivity reactions to either the drug substances or inactive ingredients of U3-1402, or to other monoclonal antibodies
• Any evidence of primary malignancy other than locally advanced or metastatic lung cancer within three years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
• Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day :

1. Corrected QT interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart

2. Left ventricular ejection fraction (LVEF) less than 50% by either ECHO or cardiac MRI or multigated acquisition scan (MUGA)

3. Resting systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg e. Myocardial infarction within six months f. NYHA Classes 2 to 4 within 28 days before treatment g. Uncontrolled angina pectoris within six months. h. Cardiac arrhythmia requiring antiarrhythmic treatment

• Active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1, Day 1.

1. Hepatitis surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR

2. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases (in the absence of liver metastasis); OR

3. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with liver metastasis and abnormal transaminases AST/ALT less than 3 ULN Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection, is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)

• Known human immunodeficiency virus (HIV) or active COVID-19 infection
• Participants under guardianship or deprived of his/her liberty by a judicial or administrative decision or incapable of giving his/her consent
• Female participants who are pregnant or breastfeeding or intend to become pregnant during the study
• Participation in another clinical trial evaluating an experimental drug (except non-interventional research)
• Evidence of clinically active spinal cord compression or brain metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive or treated brain metastases who are asymptomatic (ie, without neurologic signs or symptoms and do not require treatment with corticosteroids or anticonvulsants) may be included in the study. Participants must have a stable neurologic status for at least 2 weeks prior to Cycle 1 Day 1
• Inadequate washout period prior to Cycle 1 Day 1, defined as:

1. Whole brain radiation therapy within 14 days before treatment or stereotactic brain radiation therapy, within 7 days before treatment

2. Any cytotoxic chemotherapy, investigational agents or other anticancer drug(s) from a previous cancer treatment regimen or clinical study, within 14 days before treatment or 5 half-lives, whichever is longer

3. Immune checkpoint inhibitor therapy, within 21 days before treatment

4. Endocrine therapy within 21 days before treatment

5. Major surgery (excluding placement of vascular access), within 28 days before treatment

6. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation, within 28 days before treatment or palliative radiation therapy within 14 days before treatment

7. Chloroquine or hydroxychloroquine within 14 days before treatment.

8. Live virus vaccination, within 28 days before treatment

• Prior treatment with an anti-HER3 antibody and/or ADC containing an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan).
• Participants with grade =2 unresolved toxicities from previous anticancer therapy (other than alopecia), as defined by the NCI-CTCAE version 5.0
• Participant with a known hypersensitivity to either the drug substances or inactive ingredients in the drug product Participant with a history of severe hypersensitivity reactions to other monoclonal antibodies Participant has any primary malignancy other than locally advanced or metastatic breast cancer within 3 years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated
• Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1, including:

1. Corrected QT interval higher than 470 ms for females and 450 ms for males according to Fridericia's formula (QTcF) and assessed based on triplicate ECGs, approximately 1 minute apart

2. Left ventricular ejection fraction (LVEF) less than 50% by either ECHO or cardiac MRI

3. Resting systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than 90 mmHg

4. Myocardial infarction within six months

5. NYHA Classes 2 to 4 within 28 days before treatment

6. Uncontrolled angina pectoris within six months.

7. Cardiac arrhythmia requiring antiarrhythmic treatment

• Participants with past or resolved hepatitis B virus (HBV) infection are eligible if:

1. Hepatitis surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR

2. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases (in the absence of liver metastasis); OR

3. HBsAg positive and HBV DNA viral load is documented to be equal or less than 2,000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with liver metastasis and abnormal transaminases AST/ALT less than 3 ULN Participants with a history of Hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection, is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer)

• Female participant who is pregnant or breastfeeding or intends to become pregnant during the study
• Participants with human immunodeficiency virus (HIV)
• Participants with any psychological, familial, sociological or geographical condition potentially hindering compliance with the study protocol procedures and follow-up schedule Participants under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
• Participation in another clinical trial evaluating an experimental drug (except non-interventional research

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• U3-1402
First infusion for 90 minutes and then infusion duration can be progressively decreased to 30 minutes if participant doesn't experience infusion related reactions (IRR)

Locations

Country	Name	City	State
France	Gustave Roussy	Villejuif

Sponsors (2)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris	Daiichi Sankyo, Inc.

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of objective response rate (ORR)	Defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) assessed by investigators	During treatment period, an average of 8 months
Secondary	Evaluation of duration of response (DoR) in the overall population and according to HER3 expression levels	Applicable to participants with either complete response (CR) or partial response (PR) and is defined as the time from the first documented CR or PR until the date of disease progression, or until the date of death. It will be evaluated in the overall population and in subgroups of patients according to their HER3 expression levels	From cycle 3 (Week 6) up to 3 years after the EoT, an average of 42 months
Secondary	Evaluation of progression free Survival (PFS) in the overall population and according to HER3 expression levels	Defined as the time date of the first dose until progression or death from any cause, whichever occurs first. It will be evaluated in the overall population and in subgroups of patients according to their HER3 expression levels	From cycle 3 (Week 6) up to 3 years after the EoT, an average of 42 months
Secondary	Evaluation of clinical benefit ratio (CBR) in the overall population and according to HER3 expression levels	Defined as the presence of at least a PR or CR, or a stable disease (SD) for more than six months under treatment. It will be evaluated in the overall population and in subgroups of patients according to their HER3 expression levels	During treatment period, an average of 8 months
Secondary	Percentage of patients experiencing adverse events		During treatment (at each cycle), at EoT and up to 47 days after EoT, an average of 9 months
Secondary	Frequency of treatment emergent adverse events (TEAEs) leading to change in treatment dose		During treatment, an average of 8 months
Secondary	Incidence of abnormal laboratory test results		During treatment (at each cycle) and at EoT an average of 8 months
Secondary	Incidence of abnormal ECG readings		During treatment and at EoT an average of 8 months
Secondary	Physical functioning sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 4, where higher scores mean worse outcome		During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and then up to 3 years after EoT, an average of 42 months
Secondary	Changes in Eastern Cooperative Oncology Group performance status [ECOG PS] based on a score from 1 to 5, where higher scores mean worse outcomes		During treatment (at each cycle) and at EoT, an average of 8 months
Secondary	Change in left ventricular ejection fraction (LVEF)		During treatment and at EoT, an average of 8 months
Secondary	Global health sub-scale score of the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) based on a scale from 1 to 7, where higher scores mean better outcome		During treatment (Cycles 1, 2, 3 and then every 2 cycles), at EoT and up to 3 years after EoT, an average of 42 months
Secondary	Severity of adverse events as assessed by CTCAE v5.		During treatment (at each cycle), at EoT and up to 47 days after EoT, an average of 9 months
Secondary	Objective response rate (ORR) according to HER3 levels	Defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) assessed by investigators and will be linked to the levels of HER3 expression	During treatment period, an average of 8 months
Secondary	Overall survival in the overall population and according to HER3 expression levels	Defined as the time from date of first dose until death.It will be evaluated in the overall population and in subgroups of patients according to their HER3 expression levels	From C1D1 until death, an average of 26 months